Do I need a medical license to prescribe GLP-1 at my medspa?

You must hold an active medical license (MD, DO, NP, or PA with prescriptive authority) to prescribe GLP-1. If you're a nurse injector or aesthetician without independent prescriptive authority, you must partner with a licensed prescriber, either employed, contracted as medical director, or part of a telehealth network. Verify your state's delegation rules with your state medical board, as some states require physician oversight for NPs and PAs.

What does a good-faith GLP-1 exam need to include?

The prescriber must document weight, BMI, comorbidities (diabetes, hypertension, cardiovascular disease), medication history, and contraindications including personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. Telehealth exams are legally permissible in most states, but some now require an in-person initial visit. Thin documentation creates liability exposure if a patient experiences pancreatitis, gastroparesis, or thyroid issues.

What's the difference between branded and compounded GLP-1 for my medspa?

Branded products (Wegovy, Zepbound) are FDA-approved with regulated quality but offer thin margins (10–20%) and variable insurance coverage; patient out-of-pocket can exceed $1,000/month. Compounded semaglutide ($200–400/month) and tirzepatide ($300–500/month) are cheaper but unregulated by the FDA, so you assume liability for quality, sterility, and potency. If using a compounder, verify state pharmacy board license, USP compliance, and third-party potency testing.

Does insurance cover Wegovy and Zepbound?

Coverage varies widely by plan. Some insurers cover Wegovy or Zepbound for BMI ≥30 or ≥27 with comorbidities; others exclude them or require prior authorization. Many patients are uninsured or underinsured for these medications, making cash-pay pricing a significant barrier. Check individual plan requirements before promising coverage to patients.

What compliance risks come with offering GLP-1 at a medspa?

GLP-1 requires a different operational and compliance posture than injectables: prescriber licensing, good-faith exams, and proper documentation are non-negotiable. If sourcing from compounders, you accept regulatory and reputational risk for quality and sterility failures. Liability exposure is real if patients experience adverse events (pancreatitis, gastroparesis) and your exam or sourcing records are inadequate.

How much margin can I make on GLP-1 compared to injectables?

Branded GLP-1 margins are thin (10–20% over acquisition cost), significantly lower than typical aesthetic injectables. Compounded GLP-1 offers higher margins due to lower acquisition cost, but you're accepting regulatory and liability risk. The real revenue opportunity lies in patient retention and upsell to aesthetic services, not GLP-1 margins alone.

Sunday, August 9, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

Business & M&AEvolus Q2 Revenue Hits $84.1M, Raises 2026 Guidancetoday RegulatoryAbbVie Wins FDA Review for BOTOX Jawline Indication2 days ago Devices & TechInMode Q2 Beats EPS Forecast, Revenue Tops Estimatestoday Devices & TechInMode Q2 Revenue Beats on Steady U.S. Device Demand2 days ago RegulatoryFDA Accepts BOTOX Masseter sBLA—Jawline Approval Path Cleartoday Business & M&AEvolus Files Material Event—Jeuveau Pricing Escalates2 days ago MarketDaewoong's NABOTA Enters Seventh Middle East Markettoday Business & M&AAbbVie Files Material Event—Allē Rebate Terms Shifting2 days ago Business & M&AHugel Posts Record H1 Earnings on Toxin Growthyesterday ComplianceEvolus Rewards Program Terms Changed—Review Nowyesterday Devices & TechInMode Q2 Revenue Beats Estimates at $95.6Myesterday Devices & TechSofwave Q2 Revenue Accelerates on Ultrasonic Demandyesterday

Market

Offering GLP-1 Weight Loss at a Medspa: Sourcing, Compliance, and Revenue Model

How to evaluate GLP-1 as a revenue line, manage sourcing and prescriber requirements, and stay compliant with state and federal regulations.

By Evan at Inside MedSpa · Jun 26, 2026

GLP-1 receptor agonists (semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Zepbound and Mounjaro) have become a significant revenue opportunity for medspas willing to add a medical-weight-loss vertical. Demand is real: patients already trust you for aesthetic outcomes and are actively seeking non-surgical metabolic solutions. But offering GLP-1 requires a different operational and compliance posture than injectables, and sourcing and reimbursement are fragmented across payers and suppliers. Here's what you need to know before you launch.

Demand and Market Reality

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/glp-1-for-medspas/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

The Beauty Health Company (HydraFacial)-13.93%e.l.f. Beauty+6.69%Hims & Hers Health+6.51%Bausch Health (Solta)+5.75%Ulta Beauty+4.89%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	5
Jul '26	20	4

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →